GlassScriptPhysician profile
Pasquale Fucci
NPI 1942257001
$8,601.16
in general payments reported to CMS, 2019-2025
51 companies · $1,582 in 2025
The $1,582 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,110 · 2020: $710 · 2021: $1,282 · 2022: $1,467 · 2023: $977 · 2024: $1,472 · 2025: $1,582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,970 · Education: $60.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,970.15 |
| Education | $60.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,315.68 | 2020-2025 | |
| Lilly USA, LLC | $1,159.02 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,078.71 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $849.30 | 2019-2025 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $533.48 | 2019-2025 | Veozah |
| Pfizer INC. | $362.57 | 2019-2025 | |
| Glaxosmithkline, LLC. | $310.75 | 2022-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Teva Pharmaceuticals USA, INC. | $289.80 | 2020-2023 | Austedo Xr, Austedo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $282.66 | 2019-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $227.02 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $225.77 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $217.79 | 2019-2025 | Verquvo, Steglatro, Belsomra |
| Abbott Laboratories | $126.42 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $118.42 | 2023-2025 | Rexulti |
| Amgen INC. | $103.50 | 2020-2021 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pasquale Fucci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.